InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,676.40
(
0.20%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.64
(
-1.56%
)
Bitcoin
60,617.89
(
-3.85%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 339

Tuesday, 09/04/2018 2:21:28 PM

Tuesday, September 04, 2018 2:21:28 PM

Post# of 438
AFMD signed a POTENTIALLY lucrative deal with RHHBY and spiked 220%

The deal is for development using the company's ROCK platform and does not include any of AFMDs lead programs. $96mn is front loaded into the $5B potential payout.

The lead programs hold significant value in their own rights and this deal lends substance to their prospects.

AFM13 has had promising efficacy in 2 early stage trials both as a monotherapy and a combo therapy.

Both of AFMD lead programs will have data before EOY/18. Part of this spike is based on the hope that one of these prrograms will garner an expedited path to FDA approval.

As for the RHHBY deal, it only extends the operational runway thru 2019. I think any further good news in 2018 is mostly built in.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up